Agumentation of antitumor immunity by genetically engineered fibrobalst cells to express both B7.1 and interleukin-7
- Title
- Agumentation of antitumor immunity by genetically engineered fibrobalst cells to express both B7.1 and interleukin-7
- Author
- 황승용
- Issue Date
- 2000-07
- Publisher
- Elservier
- Citation
- VACCINE, v. 18, issue. 25, page. 2886-2894
- Abstract
- Mouse fibroblasts (H-2b) were genetically engineered to express a costimulatory B7.1 and an interleukin-7 (IL-7; Fb/B7.1/IL7). The Fb/B7.1/IL7 cells were then pulsed with an ovalbumin (OVA) epitope (amino acids 257–264, SIINFEKL, H-2 Kb restricted; Fb/B7.1/IL7/OVA) and tested for the induction of OVA-specific cytotoxic T lymphocytes (CTLs) in C57BL/6 mice (H-2b). The genetically engineered fibroblasts lacking either B7.1 or IL-7 were constructed and used as controls. Immunization with the Fb/B7.1/IL7/OVA cells induced strong cytotoxic activities against OVA-expressing EL4 (EG7) tumor cells. The magnitude of the cytotoxic response in mice with the Fb/B7.1/IL7/OVA cells was significantly higher than the response in mice immunized with any other cell constructs. CD8+ T cells were a major effector cell-type of antitumor response in the immunized mice with the Fb/B7.1/IL7/OVA cells. Furthermore, immunization with the Fb/B7.1/IL7/OVA cells significantly prolonged the survival period of mice when the mice were injected with EG7 tumor cells one week after the immunization. These results suggest that fibroblasts can be genetically modified to an efficient cell vaccine for the induction of antitumor response.
- URI
- https://www.sciencedirect.com/science/article/pii/S0264410X0000061X#!https://repository.hanyang.ac.kr/handle/20.500.11754/162984
- ISSN
- 0264-410X; 1873-2518
- DOI
- 10.1016/S0264-410X(00)00061-X
- Appears in Collections:
- COLLEGE OF SCIENCE AND CONVERGENCE TECHNOLOGY[E](과학기술융합대학) > MOLECULAR AND LIFE SCIENCE(분자생명과학과) > Articles
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML